About Fortress Biotech, Inc. 
Fortress Biotech, Inc.
Pharmaceuticals & Biotechnology
Fortress Biotech, Inc.(Fortress) is a biopharmaceutical company that acquires, develops and commercializes novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.
Company Coordinates 
Company Details
2 Gansevoort St Fl 9 , NEW YORK NY : 10014-1667
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 8 Schemes (3.96%)
Foreign Institutions
Held by 9 Foreign Institutions (2.18%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Dr. Lindsay Rosenwald
Executive Chairman of the Board, President, Chief Executive Officer
Dr. Eric Rowinsky
Co-Vice Chairman and Director
Mr. Michael Weiss
Executive Vice Chairman - Strategic Development, Director
Dr. Jimmie Harvey
Independent Director
Mr. Malcolm Hoenlein
Independent Director
Mr. Dov Klein
Independent Director
Mr. J. Jay Lobell
Independent Director
Mr. Kevin Lorenz
Independent Director
Revenue and Profits:
Net Sales:
16 Million
(Quarterly Results - Jun 2025)
Net Profit:
-12 Million
Pharmaceuticals & Biotechnology
USD 107 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.42
-210.42%
2.44






